These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

274 related articles for article (PubMed ID: 29682098)

  • 41. [K-ras mutation analysis in ovarian serous borderline and malignant tumors].
    Ma L; Guo LN; Liang ZY; Ren XY; Wu SF
    Zhonghua Bing Li Xue Za Zhi; 2006 Dec; 35(12):714-8. PubMed ID: 17374253
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Pattern of HER-2 Gene Amplification and Protein Expression in Benign, Borderline, and Malignant Ovarian Serous and Mucinous Neoplasms.
    Mohammed RAA; Makboul R; Elsers DAH; Elsaba TMAM; Thalab AMAB; Shaaban OM
    Int J Gynecol Pathol; 2017 Jan; 36(1):50-57. PubMed ID: 27309616
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Methylation-associated silencing of SFRP1 gene in high-grade serous ovarian carcinomas.
    Kardum V; Karin V; Glibo M; Skrtic A; Martic TN; Ibisevic N; Skenderi F; Vranic S; Serman L
    Ann Diagn Pathol; 2017 Dec; 31():45-49. PubMed ID: 29146058
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Rapid On-site Molecular Evaluation in thyroid cytopathology: A same-day cytological and molecular diagnosis.
    De Luca C; Sgariglia R; Nacchio M; Pisapia P; Migliatico I; Clery E; Gragnano G; Campione S; Vigliar E; Malapelle U; De Dominicis G; Bellevicine C; Troncone G
    Diagn Cytopathol; 2020 Apr; 48(4):300-307. PubMed ID: 31904908
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Intraoperative Diagnosis Support Tool for Serous Ovarian Tumors Based on Microarray Data Using Multicategory Machine Learning.
    Park JS; Choi SB; Kim HJ; Cho NH; Kim SW; Kim YT; Nam EJ; Chung JW; Kim DW
    Int J Gynecol Cancer; 2016 Jan; 26(1):104-13. PubMed ID: 26512784
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Usefulness of immunohistochemistry for the detection of the BRAF V600E mutation in ovarian serous borderline tumors.
    Hayashi Y; Sasaki H; Takeshita S; Nishikawa R; Nishikawa H; Arakawa A; Yamashita Y; Takahashi S; Sugiura-Ogasawara M
    Oncol Rep; 2014 Nov; 32(5):1815-9. PubMed ID: 25174456
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Long-term Behavior of Serous Borderline Tumors Subdivided Into Atypical Proliferative Tumors and Noninvasive Low-grade Carcinomas: A Population-based Clinicopathologic Study of 942 Cases.
    Vang R; Hannibal CG; Junge J; Frederiksen K; Kjaer SK; Kurman RJ
    Am J Surg Pathol; 2017 Jun; 41(6):725-737. PubMed ID: 28248817
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Mutational analysis of K-ras segregates ovarian serous carcinomas into two types: invasive MPSC (low-grade tumor) and conventional serous carcinoma (high-grade tumor).
    Singer G; Shih IeM; Truskinovsky A; Umudum H; Kurman RJ
    Int J Gynecol Pathol; 2003 Jan; 22(1):37-41. PubMed ID: 12496696
    [TBL] [Abstract][Full Text] [Related]  

  • 49. High expression of NQO1 is associated with poor prognosis in serous ovarian carcinoma.
    Cui X; Li L; Yan G; Meng K; Lin Z; Nan Y; Jin G; Li C
    BMC Cancer; 2015 Apr; 15():244. PubMed ID: 25885439
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Expression of selected epithelial-mesenchymal transition transcription factors in serous borderline ovarian tumors and type I ovarian cancers.
    Sadlecki P; Jóźwicki J; Antosik P; Grabiec M
    Tumour Biol; 2018 Jun; 40(6):1010428318784807. PubMed ID: 29952249
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Expression of BRAF V600E mutant protein in epithelial ovarian tumors.
    Preusser M; Capper D; Berghoff AS; Horvat R; Wrba F; Schindl M; Schoppmann SF; von Deimling A; Birner P
    Appl Immunohistochem Mol Morphol; 2013 Mar; 21(2):159-64. PubMed ID: 22820660
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Molecular subtypes of serous borderline ovarian tumor show distinct expression patterns of benign tumor and malignant tumor-associated signatures.
    Curry EW; Stronach EA; Rama NR; Wang YY; Gabra H; El-Bahrawy MA
    Mod Pathol; 2014 Mar; 27(3):433-42. PubMed ID: 23948749
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Mammary serine protease inhibitor and CD138 immunohistochemical expression in ovarian serous and clear cell carcinomas.
    Hasby EA
    Tumour Biol; 2016 Apr; 37(4):4889-900. PubMed ID: 26526579
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Mixed endometrial carcinomas with a "low-grade serous"-like component: a clinicopathologic, immunohistochemical, and molecular genetic study.
    Espinosa I; D'Angelo E; Corominas M; Gonzalez A; Prat J
    Hum Pathol; 2018 Jan; 71():65-73. PubMed ID: 29079180
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Mutation of K-ras protooncogene is associated with histological subtypes in human mucinous ovarian tumors.
    Ichikawa Y; Nishida M; Suzuki H; Yoshida S; Tsunoda H; Kubo T; Uchida K; Miwa M
    Cancer Res; 1994 Jan; 54(1):33-5. PubMed ID: 8261457
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Ovarian Combined Low-grade Serous and Mesonephric-like Adenocarcinoma: Further Evidence for A Mullerian Origin of Mesonephric-like Adenocarcinoma.
    McCluggage WG; Vosmikova H; Laco J
    Int J Gynecol Pathol; 2020 Jan; 39(1):84-92. PubMed ID: 30575604
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Molecular alterations in indolent, aggressive and recurrent ovarian low-grade serous carcinoma.
    McIntyre JB; Rambau PF; Chan A; Yap S; Morris D; Nelson GS; Köbel M
    Histopathology; 2017 Feb; 70(3):347-358. PubMed ID: 27575406
    [TBL] [Abstract][Full Text] [Related]  

  • 58. BRAF mutation is associated with a specific cell type with features suggestive of senescence in ovarian serous borderline (atypical proliferative) tumors.
    Zeppernick F; Ardighieri L; Hannibal CG; Vang R; Junge J; Kjaer SK; Zhang R; Kurman RJ; Shih IeM
    Am J Surg Pathol; 2014 Dec; 38(12):1603-11. PubMed ID: 25188864
    [TBL] [Abstract][Full Text] [Related]  

  • 59. The status of epidermal growth factor receptor in borderline ovarian tumours.
    Showeil R; Romano C; Valganon M; Lambros M; Trivedi P; Van Noorden S; Sriraksa R; El-Kaffash D; El-Etreby N; Natrajan R; Foroni L; Osborne R; El-Bahrawy M
    Oncotarget; 2016 Mar; 7(9):10568-77. PubMed ID: 26870997
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Extreme Outlier Analysis Identifies Occult Mitogen-Activated Protein Kinase Pathway Mutations in Patients With Low-Grade Serous Ovarian Cancer.
    Grisham RN; Sylvester BE; Won H; McDermott G; DeLair D; Ramirez R; Yao Z; Shen R; Dao F; Bogomolniy F; Makker V; Sala E; Soumerai TE; Hyman DM; Socci ND; Viale A; Gershenson DM; Farley J; Levine DA; Rosen N; Berger MF; Spriggs DR; Aghajanian CA; Solit DB; Iyer G
    J Clin Oncol; 2015 Dec; 33(34):4099-105. PubMed ID: 26324360
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 14.